Navigation Links
New Analysis Shows Efficacy of SIMPONI(TM) (golimumab) in Anti-TNF Experienced Rheumatoid Arthritis Patients
Date:6/9/2009

Anti-TNF Experienced Patients Demonstrated Improvement With Every-Four-Week Subcutaneous SIMPONI Despite Previous Medication or Reason for Discontinuation

COPENHAGEN, June 9 /PRNewswire/ -- A new analysis demonstrated that a greater proportion of patients with moderately to severely active rheumatoid arthritis (RA) who had prior treatment with anti-tumor necrosis factor (TNF)-alpha agents and received subcutaneous injections of SIMPONI(TM) (golimumab) once every four weeks experienced significant improvements in signs and symptoms through week 24, compared with patients receiving placebo. Patients continued to receive stable doses of methotrexate, sulfasalazine and/or hydroxychloroquine if receiving them at baseline. These data were presented at the 2009 European League Against Rheumatism (EULAR) Annual Congress.

Findings from the GOlimumab After Former anti-TNF Therapy Evaluated in RA (GO-AFTER) study, demonstrated that patients previously treated with adalimumab, etanercept or infliximab responded to and tolerated SIMPONI regardless of the type of prior anti-TNF therapy, as well as the number of prior therapies or reason for discontinuation. According to the study, 39 percent of patients receiving SIMPONI whose prior anti-TNF-alpha therapy had been discontinued due to a lack of efficacy achieved at least a 20 percent improvement in arthritis symptoms (ACR 20) at week 14, compared with 18 percent of patients receiving placebo (p<0.001). Thirty-four percent of patients receiving SIMPONI whose prior anti-TNF-alpha therapy had been discontinued for all other reasons achieved ACR 20, compared with 20 percent of patients receiving placebo (p=0.027).

"Golimumab has shown promise in the treatment of rheumatoid arthritis patients who have previously discontinued other anti-TNF-alpha therapies," said Josef S. Smolen, MD, Professor and Chairman, Departm
'/>"/>

SOURCE Centocor Ortho Biotech Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related medicine technology :

1. Meta-Analysis of Clinical Data Showed No Increased Risk of Cardiovascular Events Associated With Exenatide Use: Data Presented at ADA 2009
2. Shire Presented Results of a New Database Analysis on Lialda(R) (Mesalamine) and Other 5-ASAs for Ulcerative Colitis at Digestive Disease Week
3. SYNTAX Analysis Finds Treatment With TAXUS(R) Express2(R) Stent System More Cost Effective Than Bypass Surgery in Patients With Complex Coronary Artery Disease
4. New MADIT II Clinical Data Analysis Shows Long-Term Survival Benefit for Implantable Defibrillator Therapy
5. New Analysis Evaluated Impact of Genetic Variation on Response to Prasugrel
6. New Imaging Analysis Predicts Brain Tumor Survival
7. Glycotex Investigational Compound GLYC-101 Achieves Accelerated Wound Closure Based on Interim Analysis
8. CRESTOR(R) Reduced CV Risk in Patients Achieving Low LDL and hsCRP Targets in New JUPITER Analysis
9. SYNTAX Analysis Finds Treatment With TAXUS(R) Express2(TM) Stents More Cost Effective Than Bypass Surgery in Many Patients With Complex Coronary Artery Disease
10. CDC Analysis Finds Unique Social and Behavior Intervention Helps Reduce MRSA Rates Up to 62% in Study Hospitals
11. Hana Biosciences Announces Successful Planned Independent Safety Analysis Supports Ability to Complete Pivotal rALLy Clinical Trial of Marqibo, Its Lead Novel Anti-Cancer Compound
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/7/2015)... , July 7, 2015 BioRx, a Diplomat ... recognized as a Top Workplace in 2015 based on a ... the Enquirer Media Group and a Philadelphia ... 22 questions and was completed by employees across the ... area, with topics ranging from workplace environment to ...
(Date:7/7/2015)... NEW YORK , July 7, 2015 /PRNewswire/ ... Welch Allyn for $2 billion in cash and ... competitive patient monitoring market, according to Kalorama Information. ... heretofore participated in the medical device and advanced ... maker of hospital beds, patient lifting devices, and ...
(Date:7/7/2015)... 7, 2015   ICD-10 Charts ( www.icd10charts.com ... development, it has officially launched its newest line ... Academy and the new 4 Step ICD-10 Implementation ... all other ICD-10 Charts resources and mobile apps, ... completely free-of-charge.  With the release of these resources, ...
Breaking Medicine Technology:BioRx Named a Top Workplace in 2015 by Enquirer Media 2BioRx Named a Top Workplace in 2015 by Enquirer Media 3Kalorama: Hill-Rom Enters Monitoring Market with Welch Allyn Purchase 2Kalorama: Hill-Rom Enters Monitoring Market with Welch Allyn Purchase 3ICD-10 Charts Releases Revolutionary Free Solution for Complete ICD-10 Preparation 2ICD-10 Charts Releases Revolutionary Free Solution for Complete ICD-10 Preparation 3ICD-10 Charts Releases Revolutionary Free Solution for Complete ICD-10 Preparation 4
... Varian Medical Systems (NYSE: VAR ) is ... at 9:30 a.m. ET on Wednesday, November 17th at ... Participating executives will include Elisha Finney, senior vice ... investor relations and corporate communications. The presentation will focus ...
... GREENSBORO, N.C., Nov. 5, 2010 Merz Pharmaceuticals announced ... Xeomin® (incobotulinumtoxinA), a botulinum toxin type A free from ... Assembly of the American Academy of Physical Medicine and ... U.S. Food and Drug Administration (FDA) approved XEOMIN on ...
Cached Medicine Technology:Xeomin® (incobotulinumtoxinA) Data To Be Presented At The 71st Annual Assembly Of The American Academy Of Physical Medicine And Rehabilitation 2Xeomin® (incobotulinumtoxinA) Data To Be Presented At The 71st Annual Assembly Of The American Academy Of Physical Medicine And Rehabilitation 3Xeomin® (incobotulinumtoxinA) Data To Be Presented At The 71st Annual Assembly Of The American Academy Of Physical Medicine And Rehabilitation 4Xeomin® (incobotulinumtoxinA) Data To Be Presented At The 71st Annual Assembly Of The American Academy Of Physical Medicine And Rehabilitation 5Xeomin® (incobotulinumtoxinA) Data To Be Presented At The 71st Annual Assembly Of The American Academy Of Physical Medicine And Rehabilitation 6
(Date:7/7/2015)... ... July 07, 2015 , ... Difass USA, a modern ... pass those long, stressful days at work is knowing that there is hopefully a ... back and stress free as imagined. Planning for a vacation can be quite stressful, ...
(Date:7/7/2015)... ... , ... The United States Centers for Disease Control and Prevention have awarded ... Multicultural AIDS Coalition $3.78 million for a five-year HIV prevention partnership that will ... transgender women, the groups at highest risk of HIV infection in the US. ...
(Date:7/7/2015)... MD (PRWEB) , ... July 07, 2015 , ... SC&H ... of Service, which aims to give back to the community through company-wide volunteering efforts. ... from SC&H Group dedicate the day to assisting those in need throughout Baltimore and ...
(Date:7/7/2015)... ... July 07, 2015 , ... The Immune Deficiency Foundation ... patient community using its IDF ePHR, an electronic personal health record powered by ... to easily track their health information, including symptoms, diagnoses, medications, infusions and other ...
(Date:7/7/2015)... ... July 07, 2015 , ... FSAstore.com today announced the launch ... holders. HSAstore.com makes it simple to use, spend and manage HSA funds with innovative ... accounts. , According to a report by Devenir , approximately 13.8 million ...
Breaking Medicine News(10 mins):Health News:Difass USA Offers Eight Tips to Help Relax and Enjoy Summer Vacation 2Health News:Difass USA Offers Eight Tips to Help Relax and Enjoy Summer Vacation 3Health News:CDC Awards Fenway Health, AIDS Action, Multicultural AIDS Coalition $3.78m For ‘Getting To Zero’ HIV Prevention Partnership 2Health News:CDC Awards Fenway Health, AIDS Action, Multicultural AIDS Coalition $3.78m For ‘Getting To Zero’ HIV Prevention Partnership 3Health News:SC&H Group Celebrates 9th Annual Day of Service 2Health News:Get Real Health Launches New Mobile App for Immune Deficiency Foundation Patient Community 2Health News:Get Real Health Launches New Mobile App for Immune Deficiency Foundation Patient Community 3Health News:Introducing HSAstore.com: A New E-commerce Site for Health Savings Account Eligible Products and Services 2Health News:Introducing HSAstore.com: A New E-commerce Site for Health Savings Account Eligible Products and Services 3
... stem cells, which may provide a treatment for tumors ... pancreatic cancer, according to new research from Memorial Sloan-Kettering ... important since pancreatic cancer has a poor prognosis and ... Investigators led by Joyce Wong, MD, surgical researcher ...
... , NEW YORK (May 6, 2011) -- Among ... meeting are physician-scientists from NewYork-Presbyterian Hospital/Columbia University Medical ... McCormick Place, Chicago. The following are two notable ... A gastroenterologist at NewYork-Presbyterian Hospital/Columbia University Medical Center ...
... gene expression of their lungs similar to that suffered by ... is the conclusion of a new study, led by Catalan ... causing these alterations. "Our objective was to analyse the ... samples of patients with COPD, whether smokers or not, and ...
... up to a year before a patient is diagnosed with ... often mistaken for other diseases. However, with this blood-based test, ... disease or not", says Christer Wingren, associate professor in Immunotechnology ... determine how far the disease has progressed. There are three ...
... post-mortem tissue archive for a study of the human form ... by coroners to participate. The Coroners, Society of England and ... public health" from potential new risks associated with variant Creutzfeldt-Jakob ... of tissue from autopsies. That is the conclusion of a ...
... (HealthDay News) -- Children conceived in winter seem to have ... study suggests. Environmental factors -- including exposure to seasonal ... play a role in the greater risk for autism among ... California, Davis researchers. The investigators analyzed data from 6.6 ...
Cached Medicine News:Health News:Oncolytic viruses effectively target and kill pancreatic cancer stem cells 2Health News:NY Presbyterian/Columbia research presented at Digestive Disease Week meeting 2Health News:Smokers undergo the same changes in gene expression as patients with COPD 2Health News:New test could give SLE patients a more tolerable life 2Health News:Coroners wrong to say no to post-mortem tissue collection, academics argue 2Health News:Winter Conception Tied to Raised Risk for Autism 2
The 920M PLUS handheld pulseoximeter provides on-the-spot bloodoximetry and heart rate readings....
Rad-5 signal extraction pulse oximeter™...
... 3100 is a small, lightweight ... worn comfortably on the patients ... activities and for overnight studies, ... WristOx is intended to give ...
The pocket-size Invacare Digit finger pulse oximeter is a convenient and economical solution to fast, reliable SpO2, pulse rate and pulse strength measurements. Its compact size is ideal for home use...
Medicine Products: